Interviews with VJHemOnc

Interviews with VJHemOnc

At the 13th Annual SOHO Meeting in Houston (Sept 3–6, 2025), Andrielle Yost, Associate Director of Public Sector Engagement at The Max Foundation, discusses the work the organization is doing to improve access to chronic lymphocytic leukemia (CLL) treatment for patients in low- and middle-income countries (LMICs). Watch the interview here.

You can also watch the interviews with Pat Garcia-Gonzalez, CEO of The Max Foundation, who presented data from our access to CML treatment program

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Pat Garcia-Gonzalez joins shortlist of nominees for UICC’s Outstanding Contribution to Cancer Control Award

    Pat Garcia-Gonzalez joins shortlist of nominees for UICC’s Outstanding Contribution to Cancer Control Award

    Pat joins Paul Farmer, President Joe Biden, and other world leaders in “Driving innovation to advance cancer control equitably”

  • Pat Garcia-Gonzalez Receives Outstanding Contribution to Cancer Control Award by UICC

    Pat Garcia-Gonzalez Receives Outstanding Contribution to Cancer Control Award by UICC

    The Max Foundation CEO recognized for unwavering dedication to global, widespread health equity

  • The Max Foundation Renews and Expands Agreement with Incyte

    The Max Foundation Renews and Expands Agreement with Incyte

    The Max Foundation has renewed and expanded its treatment-access agreement with Incyte in Europe. The agreement will now provide treatment access for up to 50 patients in Eastern Europe and Central Asia.